Literature DB >> 31812935

Leukoencephalopathy after prophylactic whole-brain irradiation with or without hippocampal sparing: a longitudinal magnetic resonance imaging analysis.

Michael Mayinger1, Johannes Kraft2, Niklas Lohaus3, Michael Weller4, Daniel Schanne2, Jana Heitmann2, Jonas Willmann2, Lotte Wilke2, Jérôme Krayenbuehl2, Stephanie Tanadini-Lang2, Matthias Guckenberger2, Nicolaus Andratschke2.   

Abstract

PURPOSE: Neurocognitive changes are well described after prophylactic or therapeutic whole-brain radiotherapy (WBRT) and have been reported as early as 3 months after radiotherapy (RT). Therefore, WBRT with protection of the hippocampal region (hippocampal avoidance, HA) has been proposed to preserve neurocognition. Our aim was to compare the risk of leukoencephalopathy after prophylactic cranial irradiation (PCI) with or without HA.
METHODS: Patients with small-cell lung cancer who received either lateral-opposed field PCI (non-HA-PCI; n = 9) or hippocampus avoidance PCI (HA-PCI; n = 9) with available magnetic resonance imaging (MRI) follow-up were identified and age matched. Pre-therapeutic and follow-up MRI after RT was analysed for leukoencephalopathy based on the Fazekas score. Bilateral cortical and subcortical brain structures were segmented and analysed for alterations in dosimetric parameters and volumes.
RESULTS: There was no significant difference of Fazekas scores between groups at baseline. Fazekas score differed in post-treatment with a median of 1 in the HA-PCI group and 2 in the non-HA-PCI group (p = 0.007). Significant increase of Fazekas score over time after RT was observed for HA-PCI patients (p = 0.001) but not for non-HA-PCI patients. Dmax (highest radiation dose) and brain volume receiving doses >25Gy were higher in HA-PCI patients. There were no significant volumetric differences for segmented brain structures between groups.
CONCLUSION: Radiological changes are more prominent after HA-PCI than after non-HA-PCI. Although no standardised neurocognitive testing was performed, the significantly increased Fazekas scores after HA-PCI are expected to interfere with neurocognitive function. Prospective long-term neurocognitive studies are warranted before HA-PCI is implemented in routine clinical practice.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hippocampal avoidance; Leukencephalopathy; Neurocognitive function; Prophylactic cranial irradiation; Whole-brain radiotherapy

Year:  2019        PMID: 31812935     DOI: 10.1016/j.ejca.2019.11.008

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  5 in total

Review 1.  Intracranial long-term complications of radiation therapy: an image-based review.

Authors:  Carrie M Carr; John C Benson; David R DeLone; Felix E Diehn; Dong Kun Kim; Kenneth W Merrell; Alex A Nagelschneider; Ajay A Madhavan; Derek R Johnson
Journal:  Neuroradiology       Date:  2021-01-04       Impact factor: 2.804

Review 2.  Impact of Hippocampal Avoidance - Prophylactic Cranial Irradiation in Small Cell Lung Cancer Patients.

Authors:  Emmanouil Maragkoudakis; Vasileios Kouloulias; Maria Grenzelia; Andromachi Kougioumtzopoulou; Anna Zygogianni; Vasileios Ramfidis; Andrianni Charpidou
Journal:  Cancer Diagn Progn       Date:  2022-05-03

3.  Patients with pretreatment leukoencephalopathy and older patients have more cognitive decline after whole brain radiotherapy.

Authors:  Matthew Chan; David Ferguson; Elaine Ni Mhurchu; Ren Yuan; Lovedeep Gondara; Michael McKenzie; Robert Olson; Brian Thiessen; Nafisha Lalani; Roy Ma; Alan Nichol
Journal:  Radiat Oncol       Date:  2020-11-25       Impact factor: 3.481

4.  Benefits of Prophylactic Cranial Irradiation in the MRI Era for Patients With Limited Stage Small Cell Lung Cancer.

Authors:  Chao Qi; Wang Li; Hanming Li; Fengyun Wen; Lu Zhou; Xiaohu Sun; Hong Yu
Journal:  Front Oncol       Date:  2022-02-28       Impact factor: 6.244

5.  Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study.

Authors:  Xiaoyang Zhai; Wanhu Li; Ji Li; Wenxiao Jia; Wang Jing; Yaru Tian; Shuhui Xu; Yuying Li; Hui Zhu; Jinming Yu
Journal:  Radiat Oncol       Date:  2021-12-05       Impact factor: 3.481

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.